Younger Teens Highly Susceptible to Lifetime Substance Abuse
Teens aged 12 to 17 who use alcohol, cannabis, tobacco, and/or illegal drugs are more likely to develop life-long substance abuse disorder than those who start at a later age, a recent study reports. The researchers published their findings in a letter to JAMA Pediatrics.
The researchers pulled data for individuals age 12 to 25 from the 2015 to 2018 National Surveys on Drug Use and Health (NSDUH) of the Substance Abuse and Mental Health Services Administration. The researchers looked at initiation dates, use in the past 12 months, lifetime use, and diagnosed substance use disorders.
Lifetime substance use among adolescents in 2018 was, on average, 26.3% for alcohol, 15.4% for cannabis, and 13.4% for tobacco. For those age 18 and over, prevalence was 79.7% for alcohol, 51.5% for cannabis, and 55.0% for tobacco.
googletag.cmd.push(function() {
window.hmAds.registerAd( ‘div-gpt-ad-in_article’ );
});
}
Continue Reading
Prevalence of cannabis use disorder was higher among adolescents (age 12-17) than young adults within 12 months of first use. Looking at lifetime use of illicit drugs in young adults, prevalence within 12 months of first use was 30.9% for heroin use disorder and 24.8% for methamphetamine use disorder.
A limitation of this study was that the NSDUH data excludes incarcerated and unhoused individuals, which means prevalence could be underestimated.
“Nevertheless,” the researchers concluded, “our results identified adolescents as highly vulnerable to SUDs, supporting the need for research to evaluate the efficacy of screening for substance use and SUDs in primary care settings and the timely treatment thereof.”
Disclosures: Dr Compton reports stock ownership in General Electric, 3M, and Pfizer Inc. No other disclosures were reported.
Reference
Volkow ND, Han B, Einstein EB, Compton WM. Prevalence of substance use disorders by time since first substance use among young people in the US. JAMA Pediatr. Published online March 29, 2021. doi:10.1001/jamapediatrics.2020.6981
-
Loading…
Loading…
Want to read more?
Please login or register first to view this content.
Teens aged 12 to 17 who use alcohol, cannabis, tobacco, and/or illegal drugs are more likely to develop life-long substance abuse disorder than those who start at a later age, a recent study reports. The researchers published their findings in a letter to JAMA Pediatrics.
The researchers pulled data for individuals age 12 to 25 from the 2015 to 2018 National Surveys on Drug Use and Health (NSDUH) of the Substance Abuse and Mental Health Services Administration. The researchers looked at initiation dates, use in the past 12 months, lifetime use, and diagnosed substance use disorders.
Lifetime substance use among adolescents in 2018 was, on average, 26.3% for alcohol, 15.4% for cannabis, and 13.4% for tobacco. For those age 18 and over, prevalence was 79.7% for alcohol, 51.5% for cannabis, and 55.0% for tobacco.
Prevalence of cannabis use disorder was higher among adolescents (age 12-17) than young adults within 12 months of first use. Looking at lifetime use of illicit drugs in young adults, prevalence within 12 months of first use was 30.9% for heroin use disorder and 24.8% for methamphetamine use disorder.
A limitation of this study was that the NSDUH data excludes incarcerated and unhoused individuals, which means prevalence could be underestimated.
“Nevertheless,” the researchers concluded, “our results identified adolescents as highly vulnerable to SUDs, supporting the need for research to evaluate the efficacy of screening for substance use and SUDs in primary care settings and the timely treatment thereof.”
Disclosures: Dr Compton reports stock ownership in General Electric, 3M, and Pfizer Inc. No other disclosures were reported.
Reference
Volkow ND, Han B, Einstein EB, Compton WM. Prevalence of substance use disorders by time since first substance use among young people in the US. JAMA Pediatr. Published online March 29, 2021. doi:10.1001/jamapediatrics.2020.6981
Show More
Please login or register first to view this content.
Copyright © 2021 Haymarket Media, Inc. All Rights Reserved
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.
Enjoying our content?
Thanks for visiting Psychiatry Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Psychiatry Advisor. Register for free and gain unlimited access to:
– Clinical News, with personalized daily picks for you
– Evidence-Based Guidance
– Conference Coverage
– Unique Psychiatry Case Studies
– Full-Length Features
– Drug Monographs
– And More
{{login-button}} {{register-button}}
Please login or register first to view this content.